S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Are We in a Bear Market? Here are the Signs
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Are We in a Bear Market? Here are the Signs
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Are We in a Bear Market? Here are the Signs
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Are We in a Bear Market? Here are the Signs
NASDAQ:MRNA

Moderna (MRNA) Stock Price, News & Analysis

$104.26
+0.41 (+0.39%)
(As of 03/18/2024 ET)
Today's Range
$103.65
$107.59
50-Day Range
$85.37
$111.98
52-Week Range
$62.55
$163.24
Volume
3.99 million shs
Average Volume
4.45 million shs
Market Capitalization
$39.83 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$129.82

Moderna MarketRank™ Stock Analysis

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
24.5% Upside
$129.82 Price Target
Short Interest
Healthy
6.59% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.71
Upright™ Environmental Score
News Sentiment
0.53mentions of Moderna in the last 14 days
Based on 42 Articles This Week
Insider Trading
Selling Shares
$12.68 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($7.35) to ($5.40) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.87 out of 5 stars

Medical Sector

243rd out of 947 stocks

Biological Products, Except Diagnostic Industry

31st out of 159 stocks

MRNA stock logo

About Moderna Stock (NASDAQ:MRNA)

Moderna Inc., founded in 2010, is a biotechnology company focused on creating transformative medicines to combat viruses and other diseases. The company utilizes messenger ribonucleic acid (mRNA) technology, which transports information from a living creature's DNA to other parts of the body. The company has experienced rapid growth due to its innovative mRNA technologies, especially as the U.S. authorized the COVID-19 vaccine developed by Moderna Inc. for human use in December 2020.

Moderna Inc. operates in multiple therapeutic areas, including infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases. Its product pipeline includes prophylactic vaccines, localized regenerative therapeutics, cancer vaccines, systemic secreted therapeutics, intratumoral immuno-oncology and systemic intracellular therapeutics. The company is also developing vaccines and therapeutics for other infectious diseases, such as influenza, hMPV+PIV3, respiratory syncytial virus, endemic HCoV, cytomegalovirus, human immunodeficiency virus, herpes simplex virus, Epstein-Barr virus and varicella-zoster virus.

Moderna Inc. is actively working to develop a range of pharmaceutical solutions and vaccines and to increase its strategic alliances. The company has seen success in its innovative mRNA technologies, and its growing partnerships have given them an edge over its competitors. 

As the company continues to advance its technologies and expand its strategic alliances, Moderna Inc. is proving to be a reliable source of transformative medicines to combat viruses and other diseases.

Moderna Inc. has formed strategic partnerships with a variety of pharmaceutical companies, including AstraZeneca PLC, Merck & Co. Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics Inc., Metagenomi Inc., the Defense Advanced Research Projects Agency, Biomedical Advanced Research and Development Authority, Institute for Life Changing Medicines and the Bill & Melinda Gates Foundation. Furthermore, the company has a collaboration and license agreement with Chiesi Farmaceutici S.P.A. 

MRNA Stock Price History

MRNA Stock News Headlines

The only AI company you should be looking at
This is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.
Novavax’s dispute resolution and upcoming earnings call (MRNA)
Novavax navigates legal settlements, earnings expectations, and competition, hoping their protein-based vaccines become a global health game-changer.
MRNA Mar 2024 122.000 put
MRNA Apr 2024 105.000 put
The only AI company you should be looking at
This is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.
MRNA Apr 2024 120.000 call
MRNA Sep 2024 60.000 call
Peering Into Moderna's Recent Short Interest
Moderna ready to take its next jab at success
MRNA Jan 2026 120.000 call
Moderna (NASDAQ:MRNA) Shares Up 8.3%
Moderna Stock: Bull vs. Bear
MRNA Jan 2026 160.000 call
Moderna CEO’s compensation dropped in 2023
See More Headlines
Receive MRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Moderna and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
3/18/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:MRNA
Fax
N/A
Employees
5,600
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$129.82
High Stock Price Target
$231.00
Low Stock Price Target
$60.00
Potential Upside/Downside
+24.5%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
15 Analysts

Profitability

Net Income
$-4,714,000,000.00
Pretax Margin
-57.56%

Debt

Sales & Book Value

Annual Sales
$6.85 billion
Book Value
$36.33 per share

Miscellaneous

Free Float
322,088,000
Market Cap
$39.83 billion
Optionable
Optionable
Beta
1.60

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Should I Buy Moderna Stock? MRNA Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Moderna was last updated on Wednesday, March 13, 2024 at 11:24 PM.

Pros

Here are some ways that investors could benefit from investing in Moderna, Inc.:

  • Moderna, Inc. is a leading biotechnology company that focuses on developing messenger RNA therapeutics and vaccines for various diseases, including COVID-19.
  • The company has a diverse pipeline of products targeting infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases, providing potential for revenue growth.
  • Moderna has established strategic partnerships with key players in the industry, such as AstraZeneca, Merck, and the Bill & Melinda Gates Foundation, enhancing its research capabilities and market reach.
  • Recent positive clinical trial results and regulatory approvals have boosted investor confidence in Moderna's products, potentially leading to stock price appreciation.
  • The increasing global demand for vaccines and therapeutics, especially in the wake of the COVID-19 pandemic, presents significant growth opportunities for Moderna in the healthcare sector.

Cons

Investors should be bearish about investing in Moderna, Inc. for these reasons:

  • Market competition in the biotechnology sector is intense, with other companies also developing mRNA-based therapies and vaccines, potentially impacting Moderna's market share and profitability.
  • Regulatory uncertainties and challenges in obtaining approvals for new products could lead to delays in commercialization and revenue generation for Moderna.
  • Investing in biotechnology companies like Moderna carries inherent risks due to the complex nature of drug development, including clinical trial failures, adverse effects, and regulatory setbacks.
  • The stock price of Moderna, Inc. may be subject to volatility, influenced by factors such as market sentiment, geopolitical events, and changes in healthcare policies, posing risks to investors.
  • Fluctuations in global vaccine demand and public health priorities could impact the sales and profitability of Moderna's products, affecting the company's financial performance.

MRNA Stock Analysis - Frequently Asked Questions

Should I buy or sell Moderna stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last year. There are currently 2 sell ratings, 8 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MRNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or sell existing shares.
View MRNA analyst ratings
or view top-rated stocks.

What is Moderna's stock price target for 2024?

15 brokers have issued twelve-month price targets for Moderna's shares. Their MRNA share price targets range from $60.00 to $231.00. On average, they anticipate the company's stock price to reach $129.82 in the next twelve months. This suggests a possible upside of 24.5% from the stock's current price.
View analysts price targets for MRNA
or view top-rated stocks among Wall Street analysts.

How have MRNA shares performed in 2024?

Moderna's stock was trading at $99.45 at the beginning of 2024. Since then, MRNA shares have increased by 4.8% and is now trading at $104.26.
View the best growth stocks for 2024 here
.

When is Moderna's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our MRNA earnings forecast
.

How were Moderna's earnings last quarter?

Moderna, Inc. (NASDAQ:MRNA) released its quarterly earnings data on Thursday, February, 22nd. The company reported $0.55 EPS for the quarter, topping analysts' consensus estimates of ($0.78) by $1.33. The firm had revenue of $2.80 billion for the quarter, compared to analyst estimates of $2.53 billion. Moderna had a negative trailing twelve-month return on equity of 10.23% and a negative net margin of 68.84%. Moderna's revenue was down 44.9% on a year-over-year basis. During the same period in the prior year, the business posted $3.61 earnings per share.

What guidance has Moderna issued on next quarter's earnings?

Moderna updated its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $4.0 billion-$4.0 billion, compared to the consensus revenue estimate of $4.5 billion.

What is Stéphane Bancel's approval rating as Moderna's CEO?

57 employees have rated Moderna Chief Executive Officer Stéphane Bancel on Glassdoor.com. Stéphane Bancel has an approval rating of 92% among the company's employees. This puts Stéphane Bancel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Moderna own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Moderna investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Johnson & Johnson (JNJ), Alibaba Group (BABA) and Zoom Video Communications (ZM).

When did Moderna IPO?

(MRNA) raised $499 million in an IPO on Friday, December 7th 2018. The company issued 21,700,000 shares at $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.

Who are Moderna's major shareholders?

Moderna's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (11.97%), Vanguard Group Inc. (8.89%), Vanguard Group Inc. (8.87%), Wellington Management Group LLP (1.89%), Capital World Investors (0.95%) and The Manufacturers Life Insurance Company (0.93%). Insiders that own company stock include Arpa Garay, David W Meline, Dustin A Moskovitz, James M Mock, Juan Andres, Lori M Henderson, Lori M Henderson, Mark D Mclaughlin, Noubar Afeyan, Paul Sagan, Shannon Thyme Klinger, Stephane Bancel, Stephen Hoge, Tal Zvi Zaks and W Don Cornwell.
View institutional ownership trends
.

How do I buy shares of Moderna?

Shares of MRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MRNA) was last updated on 3/19/2024 by MarketBeat.com Staff

From Our Partners